本帖最后由 老马 于 2013-3-13 13:43 编辑 ( F) x/ k+ `) w% z/ _ Y
" f. s+ K- W/ G- S# O+ h健择（吉西他滨）+顺铂+阿瓦斯汀( e$ g' e+ }& Y) _" S: a0 g
Gemzar +Cisplatin + Avastin. V& _6 a8 i5 T& }, ?
http://annonc.oxfordjournals.org/content/21/9/1804.full
/ k9 Z, y0 k3 o' YOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) - F. `$ K! J0 q$ C9 Q
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
) w4 [! C+ _% \5 D: x# ~Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
& X1 I/ g9 q5 d @, }2 Q% S
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 294)
& M# T& M; T( L$ V4 ~ T' v8 D华为网盘附件：
+ E0 M, L! K$ `2 f" F, I【华为网盘】ava.JPG
$ B* a+ u, a! u: e! z. Q9 i |
显身卡
